[{"id":"02e83317-1e46-4ec1-8ee3-e88e0be802c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02321501","created_at":"2021-01-18T11:00:33.247Z","updated_at":"2024-07-02T16:34:27.615Z","phase":"Phase 1","brief_title":"Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02321501","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ROS1","pipe":" | ","alterations":" ALK positive • ROS1 rearrangement","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Zykadia (ceritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/22/2016","start_date":" 06/22/2016","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-10"},{"id":"ca7e4b34-6f76-4ea3-8c6b-e39973324752","acronym":"NRG-LU003","url":"https://clinicaltrials.gov/study/NCT03737994","created_at":"2023-11-21T21:15:46.432Z","updated_at":"2024-07-02T16:34:37.095Z","phase":"Phase 2","brief_title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03737994 - NRG-LU003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" ALK positive • MET amplification • ALK rearrangement","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • MET amplification • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 07/21/2021","primary_completion_date":" 07/21/2021","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-06-07"},{"id":"59529bbb-f615-4981-937f-6ac29b7ec1c3","acronym":"PIKACHU","url":"https://clinicaltrials.gov/study/NCT04322890","created_at":"2021-01-18T20:56:40.742Z","updated_at":"2024-07-02T16:34:59.292Z","phase":"Phase 2","brief_title":"Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation","source_id_and_acronym":"NCT04322890 - PIKACHU","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation • ROS1 positive • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • gefitinib • Rozlytrek (entrectinib) • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Ameile (aumolertinib) • Orpathys (savolitinib) • Ivesa (firmonertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2027","study_completion_date":" 12/24/2027","last_update_posted":"2024-06-04"},{"id":"a3255986-c4de-4a9b-bae3-7e5b9fce11d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03611738","created_at":"2021-01-18T17:45:09.767Z","updated_at":"2024-07-02T16:35:04.848Z","phase":"Phase 1","brief_title":"Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC","source_id_and_acronym":"NCT03611738","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Zykadia (ceritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-05-08"},{"id":"bc0153fa-3f27-4593-8ca6-41236ea47eb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03501368","created_at":"2021-01-18T17:13:51.868Z","updated_at":"2024-07-02T16:35:07.011Z","phase":"Phase 1","brief_title":"Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma","source_id_and_acronym":"NCT03501368","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Zykadia (ceritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/27/2018","start_date":" 06/27/2018","primary_txt":" Primary completion: 10/28/2022","primary_completion_date":" 10/28/2022","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-04-30"},{"id":"25179c5b-c443-4dc5-8695-a99257e723d2","acronym":"PEDS-PLAN","url":"https://clinicaltrials.gov/study/NCT02559778","created_at":"2021-01-18T12:23:35.740Z","updated_at":"2024-07-02T16:35:10.996Z","phase":"Phase 2","brief_title":"Pediatric Precision Laboratory Advanced Neuroblastoma Therapy","source_id_and_acronym":"NCT02559778 - PEDS-PLAN","lead_sponsor":"Giselle Sholler","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • sorafenib • Zykadia (ceritinib) • Zolinza (vorinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2024-04-08"},{"id":"40e5938b-ca20-48e3-a63c-9af4d6ee2171","acronym":"","url":"https://clinicaltrials.gov/study/NCT05489887","created_at":"2022-08-05T13:57:17.217Z","updated_at":"2024-07-02T16:35:11.027Z","phase":"Phase 2","brief_title":"Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma","source_id_and_acronym":"NCT05489887","lead_sponsor":"Giselle Sholler","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zykadia (ceritinib) • Danyelza (naxitamab-gqgk)"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 09/14/2022","start_date":" 09/14/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2033","study_completion_date":" 09/01/2033","last_update_posted":"2024-04-08"},{"id":"ba4e3b9b-44a1-44f3-a9c5-3716ed933db4","acronym":"ASCEND-4","url":"https://clinicaltrials.gov/study/NCT01828099","created_at":"2021-01-17T17:22:25.673Z","updated_at":"2024-07-02T16:35:22.326Z","phase":"Phase 3","brief_title":"LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01828099 - ASCEND-4","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Zykadia (ceritinib) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 376","initiation":"Initiation: 07/09/2013","start_date":" 07/09/2013","primary_txt":" Primary completion: 06/24/2016","primary_completion_date":" 06/24/2016","study_txt":" Completion: 01/07/2024","study_completion_date":" 01/07/2024","last_update_posted":"2024-01-24"},{"id":"458cb283-b41f-46c8-9cf0-1513a2f0ecd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01828112","created_at":"2021-01-17T17:22:24.644Z","updated_at":"2024-07-02T16:35:27.573Z","phase":"Phase 3","brief_title":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib","source_id_and_acronym":"NCT01828112","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • docetaxel • Zykadia (ceritinib) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 231","initiation":"Initiation: 06/28/2013","start_date":" 06/28/2013","primary_txt":" Primary completion: 01/26/2016","primary_completion_date":" 01/26/2016","study_txt":" Completion: 11/10/2023","study_completion_date":" 11/10/2023","last_update_posted":"2023-11-30"},{"id":"d2204f9f-cb2f-42ad-8ead-6b5fd4c0fd62","acronym":"ALTA-2","url":"https://clinicaltrials.gov/study/NCT03535740","created_at":"2021-01-18T17:24:57.716Z","updated_at":"2024-07-02T16:35:38.969Z","phase":"Phase 2","brief_title":"A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib","source_id_and_acronym":"NCT03535740 - ALTA-2","lead_sponsor":"Ariad Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib) • Zykadia (ceritinib) • Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 01/31/2019","start_date":" 01/31/2019","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2023-08-25"},{"id":"f1400e73-8f3b-42a8-a2b3-caffed3589a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02227940","created_at":"2021-01-18T10:26:56.668Z","updated_at":"2024-07-02T16:36:06.759Z","phase":"Phase 1","brief_title":"Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02227940","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Zykadia (ceritinib) • albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 01/08/2015","start_date":" 01/08/2015","primary_txt":" Primary completion: 12/27/2018","primary_completion_date":" 12/27/2018","study_txt":" Completion: 02/12/2019","study_completion_date":" 02/12/2019","last_update_posted":"2022-07-25"},{"id":"64a51d5e-8590-4765-9386-0f073045206f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01634763","created_at":"2021-01-18T07:01:36.466Z","updated_at":"2024-07-02T16:36:37.150Z","phase":"Phase 1","brief_title":"Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)","source_id_and_acronym":"NCT01634763","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK translocation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zykadia (ceritinib)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2020-12-19"},{"id":"0b405312-180b-4a62-82ab-aef5c77eed55","acronym":"","url":"https://clinicaltrials.gov/study/NCT02292550","created_at":"2021-01-18T10:48:19.009Z","updated_at":"2024-07-02T16:36:37.189Z","phase":"Phase 1","brief_title":"Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.","source_id_and_acronym":"NCT02292550","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zykadia (ceritinib) • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 05/14/2015","start_date":" 05/14/2015","primary_txt":" Primary completion: 09/26/2018","primary_completion_date":" 09/26/2018","study_txt":" Completion: 09/26/2018","study_completion_date":" 09/26/2018","last_update_posted":"2020-12-17"},{"id":"eb98d175-5a34-46f6-845c-f629ab6302c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02276027","created_at":"2021-01-18T10:42:42.037Z","updated_at":"2024-07-02T16:36:37.310Z","phase":"Phase 2","brief_title":"A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02276027","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Mektovi (binimetinib) • Zykadia (ceritinib) • Tabrecta (capmatinib) • luminespib (AUY922)"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 01/20/2015","start_date":" 01/20/2015","primary_txt":" Primary completion: 10/15/2019","primary_completion_date":" 10/15/2019","study_txt":" Completion: 10/15/2019","study_completion_date":" 10/15/2019","last_update_posted":"2020-12-16"},{"id":"83689c09-e291-49ec-b688-06e38b94435f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02605746","created_at":"2021-01-18T12:39:25.458Z","updated_at":"2024-07-02T16:36:37.444Z","phase":"Phase 1","brief_title":"Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis","source_id_and_acronym":"NCT02605746","lead_sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zykadia (ceritinib)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 02/17/2016","start_date":" 02/17/2016","primary_txt":" Primary completion: 11/29/2018","primary_completion_date":" 11/29/2018","study_txt":" Completion: 07/12/2019","study_completion_date":" 07/12/2019","last_update_posted":"2020-12-11"},{"id":"21536d9a-d0c4-4025-a52e-c66c6e11b15e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01742286","created_at":"2021-01-17T17:51:56.749Z","updated_at":"2024-07-02T16:36:44.423Z","phase":"Phase 1","brief_title":"Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)","source_id_and_acronym":"NCT01742286","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zykadia (ceritinib)"],"overall_status":"Completed","enrollment":" Enrollment 83","initiation":"Initiation: 08/28/2013","start_date":" 08/28/2013","primary_txt":" Primary completion: 04/26/2019","primary_completion_date":" 04/26/2019","study_txt":" Completion: 04/26/2019","study_completion_date":" 04/26/2019","last_update_posted":"2020-06-09"},{"id":"4d52c60e-7fdc-4e41-a332-e9519d5710e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02729961","created_at":"2021-01-18T13:21:50.904Z","updated_at":"2024-07-02T16:36:54.718Z","phase":"Phase 1/2","brief_title":"Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma","source_id_and_acronym":"NCT02729961","lead_sponsor":"University of Washington","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zykadia (ceritinib) • Adcetris (brentuximab vedotin)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/03/2018","start_date":" 01/03/2018","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/01/2023","study_completion_date":" 07/01/2023","last_update_posted":"2019-10-10"},{"id":"a83b7e71-f3bb-41fd-84d4-90b73ff208a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02289144","created_at":"2021-01-18T10:47:25.802Z","updated_at":"2024-07-02T16:36:57.582Z","phase":"Phase 2","brief_title":"Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer","source_id_and_acronym":"NCT02289144","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" ALK","pipe":" | ","alterations":" ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zykadia (ceritinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2019","study_completion_date":" 01/01/2019","last_update_posted":"2019-07-30"},{"id":"f5c3ba6d-e947-41a8-b6a5-f1be3de3f3ca","acronym":"ASCEND-3","url":"https://clinicaltrials.gov/study/NCT01685138","created_at":"2021-01-18T07:18:26.152Z","updated_at":"2024-07-02T16:37:01.310Z","phase":"Phase 2","brief_title":"LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01685138 - ASCEND-3","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Zykadia (ceritinib)"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 12/20/2012","start_date":" 12/20/2012","primary_txt":" Primary completion: 01/22/2018","primary_completion_date":" 01/22/2018","study_txt":" Completion: 01/22/2018","study_completion_date":" 01/22/2018","last_update_posted":"2019-03-26"},{"id":"5486bd4c-6e59-4220-a38a-06f852e7d147","acronym":"","url":"https://clinicaltrials.gov/study/NCT01283516","created_at":"2021-01-17T17:22:24.870Z","updated_at":"2024-07-02T16:37:01.654Z","phase":"Phase 1","brief_title":"A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase","source_id_and_acronym":"NCT01283516","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK translocation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zykadia (ceritinib)"],"overall_status":"Completed","enrollment":" Enrollment 304","initiation":"Initiation: 01/24/2011","start_date":" 01/24/2011","primary_txt":" Primary completion: 05/03/2016","primary_completion_date":" 05/03/2016","study_txt":" Completion: 05/03/2016","study_completion_date":" 05/03/2016","last_update_posted":"2019-03-15"},{"id":"2a1a433d-f2d4-44d6-804c-50d51d9fe5e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02040870","created_at":"2021-01-17T17:31:30.637Z","updated_at":"2024-07-02T16:37:02.631Z","phase":"Phase 1/2","brief_title":"LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib","source_id_and_acronym":"NCT02040870","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Zykadia (ceritinib)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 03/07/2014","start_date":" 03/07/2014","primary_txt":" Primary completion: 07/27/2017","primary_completion_date":" 07/27/2017","study_txt":" Completion: 07/27/2017","study_completion_date":" 07/27/2017","last_update_posted":"2019-02-20"},{"id":"ad9a97fd-de16-400a-b6ae-7e348e48782b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03399487","created_at":"2021-01-18T16:46:34.624Z","updated_at":"2024-07-02T16:37:03.940Z","phase":"Phase 2","brief_title":"A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement","source_id_and_acronym":"NCT03399487","lead_sponsor":"Yonsei University","biomarkers":" BRAF • ROS1","pipe":" | ","alterations":" ROS1 rearrangement","tags":["BRAF • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zykadia (ceritinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 46","initiation":"Initiation: 07/24/2018","start_date":" 07/24/2018","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2019-01-11"},{"id":"da22970b-207a-40a2-804d-8e240d30d355","acronym":"","url":"https://clinicaltrials.gov/study/NCT01964157","created_at":"2021-01-18T08:55:36.499Z","updated_at":"2024-07-02T16:37:03.913Z","phase":"Phase 2","brief_title":"An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement","source_id_and_acronym":"NCT01964157","lead_sponsor":"Yonsei University","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 rearrangement","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zykadia (ceritinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 32","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-01-11"},{"id":"4d5c0340-6c32-461c-8cb4-fe3bc2d16db1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01685060","created_at":"2021-01-18T07:18:24.044Z","updated_at":"2024-07-02T16:37:20.931Z","phase":"Phase 2","brief_title":"LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib","source_id_and_acronym":"NCT01685060","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Zykadia (ceritinib)"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 11/26/2012","start_date":" 11/26/2012","primary_txt":" Primary completion: 03/29/2016","primary_completion_date":" 03/29/2016","study_txt":" Completion: 03/29/2016","study_completion_date":" 03/29/2016","last_update_posted":"2017-06-19"}]